Translation of pharmacogenetics to clinical practice: What will it take?

Expert Review of Clinical Pharmacology

Volumn 5, Issue 2, 2012, Pages 101-103

  Slaughter, Richard L ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

clopidogrel; genetic testing; personalized medicine; pharmacogenetics

Indexed keywords

ANTIDEPRESSANT AGENT; ARYLDIALKYLPHOSPHATASE 1; CARBAMAZEPINE; CLOPIDOGREL; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUOROURACIL; HLA B ANTIGEN; IRINOTECAN; MORPHINE; NEUROLEPTIC AGENT; PHENYTOIN; TAMOXIFEN; WARFARIN;

ALLELE; CLINICAL PRACTICE; DRUG LABELING; DRUG METABOLISM; GENERAL PRACTITIONER; GENETIC SCREENING; GENOTYPE; GLUCURONIDATION; HEART INFARCTION; HUMAN; NEUTROPENIA; PHARMACIST; PHARMACOGENETICS; REVASCULARIZATION; REVIEW; STENT THROMBOSIS;

DIAGNOSTIC TESTS, ROUTINE; HUMANS; PHARMACOGENETICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84858422325     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.77     Document Type: Review

References (16)

1. Szabo L. Genetic tests can predict who needs higher doses of Plavix. USA Today. 16th November 2011.
2. Mrazek DA, Lerman C. Facilitating clinical implementation of pharmacogenomics. J. Amer. Med. Assoc. 306, 304-305 (2011).
3. Brandt JT, Kirkwood S, Mukopadhay N. CYP2C19. 2 polymorphism contributes to a diminished pharmacodynamic response to clopidogrel. J. Am. Coll. Cardiol. 47(Suppl.), 380A (2006).
4. Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849-857 (2009).
5. Collet JP, Hulot JS, Pena A, Villard E, Estave JB, Silvain J. Cytochrome P450 CYP 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 373, 309-317 (2009).
6. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrier K. Cytochrome P450 2C 19 loss-of-function polymorphism and stent thrombosis following coronary intervention. Eur. Heart J. 30, 916-922 (2009).
7. Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
8. Malek LA, Przyluski J, Spiewak M et al. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology 117(2), 81-87 (2010).
9. Bauer T, Boumann HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. Br. Med. J. doi:10.1136/bmj.d4588 (2011) (Epub ahead of print).
10. Bouman HJ, Schomig E, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17(1), 110-116 (2010).
11. Hulot JS, Collet JP, Cayla G et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ. Cardiovasc. Interv. 1, 4(5), 422-428 (2011).
12. Mega JL, Hochholzer W, Frelinger AL 3rd et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA doi:10.1001/jama.2011.1703 (2011) (Epub ahead of print).
13. Qureshi Z, Hobson AR. Clopidogrel 'resistance': where are we now? Cardiovasc. Ther. doi:10.1111/j.1755-5922.2011.00296.x. (2011) (Epub ahead of print).
14. Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents: Towards personalized therapy? Nat. Rev. Cardiol. 8, 560-571 (2011).
15. Murphy JE, Green JS, Adams LA, Squire RB, Kuo GM, McKay A. Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States. Am. J. Pharm. Educ. 74, 7 (2010).
16. Green JS, O'Brien TJ, Chiappinelli VA, Harralson AF. Pharmacogenomics instruction in US and Canadian medical schools: Implications for personalized medicine. Pharmacogenomics 11, 1331-1340 (2010).